Other current therapies for the treatment of SMA, such as the use of intrathecal antisense oligonucleotides (ASO), are site-specific for the central nervous system19, therefore have an effect on compartmentalized SMN protein levels and require repeated administration every four months.20 This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.